Product menu

SHINGRIX: Recommendations from NACI

NACI Recommendations

Checkmark icon

The National Advisory Committee on Immunization (NACI) recommends:1

SHINGRIX should be offered to adults ≥50 years of age without contraindications

(strong recommendation).

SHINGRIX should be offered to adults ≥50 years of age without contraindications who have previously been vaccinated with live zoster vaccine

(strong recommendation).

SHINGRIX should be offered to adults ≥50 years of age without contraindications who have had a previous episode of herpes zoster

(strong recommendation).

SHINGRIX may be considered for immunocompromised adults ≥50 years of age

(discretionary recommendation).

According to NACI, a strong recommendation applies to most individuals and should be followed, unless a clear and compelling rationale for an alternative approach is present. A discretionary recommendation may be considered for some individuals in some circumstances. Alternative approaches may be reasonable.1

Refer to the NACI statement on the Public Health Agency website for further information.

© All rights reserved. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccine. Public Health Agency of Canada modified: 2018. Adapted and reproduced with permission from the Minister of Health, 2018.

Graph icon

Efficacy data for SHINGRIX2

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.2

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.1

Learn more
Vaccine icon

Find out about SHINGRIX dosing and administration

Discover more about administering the vaccine and discussing shingles and vaccination with your patients.

Learn more

References:

  1. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  2. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24